Zenas BioPharma, Inc.

Zenas is a clinical-stage biopharmaceutical company that develops therapies for patients with autoimmune and inflammatory diseases. It acquires and develops product candidates directed at immune targets, without having any approved commercial products or sales revenue. Its lead candidate, obexelimab, is a monoclonal antibody that inhibits B-cell activity without cell destruction for conditions including immunoglobulin G4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus. The company also advances orelabrutinib for progressive forms of multiple sclerosis, along with early-stage candidates ZB021 and ZB022. Its end users are patients suffering from autoimmune conditions.

The provided text does not disclose the company's headquarters location. Operationally, the firm conducts clinical trials internationally across several countries, including the United States, the United Kingdom, Hungary, Poland, the Czech Republic, and Slovakia, dosing hundreds of clinical subjects. It maintains worldwide development rights for select pipeline assets while partnering with pharmaceutical companies across regional markets, including greater China and parts of the Asia-Pacific region.

Summary of the business section of Zenas BioPharma's latest annual report, written by StockData.

“As of February 28, 2026, we had 167 full-time employees, consisting of clinical, scientific, development, medical affairs, technical operations, regulatory, finance, legal and operational personnel.”